NRAS/HRAS/KRAS Recombinant Monoclonal Antibody

The RAS family of small GTPases—comprising NRAS, HRAS, and KRAS—represents one of the most intensively studied signaling nodes in cancer biology. These molecular switches cycle between active GTP-bound and inactive GDP-bound states to regulate cell proliferation, differentiation, and survival through the MAPK and PI3K pathways. Mutations in RAS genes occur in approximately 30% of all human cancers, with KRAS alterations particularly prevalent in pancreatic, colorectal, and lung adenocarcinomas. Understanding RAS expression patterns and localization remains essential for researchers investigating oncogenic signaling mechanisms and therapeutic resistance.

This recombinant monoclonal antibody (clone 2D11) targets a conserved epitope shared across NRAS, HRAS, and KRAS, enabling simultaneous detection of all three family members in a single experiment. The recombinant production method ensures that every lot delivers identical binding characteristics, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. As a sequence-defined reagent, this antibody provides the reproducibility that rigorous experimental workflows demand.

Validation studies demonstrate reliable performance across multiple platforms. Immunohistochemistry staining at 1:100 dilution reveals clear signal in paraffin-embedded human small intestine and liver cancer tissues using citrate buffer antigen retrieval, offering researchers a validated approach for examining RAS expression in both normal and malignant contexts. Flow cytometry analysis of 786-O renal carcinoma cells confirms intracellular detection capability, with distinct positive shifts compared to isotype controls at 1:100 dilution following formaldehyde fixation and Triton X-100 permeabilization.

Whether you are mapping RAS expression across tumor microenvironments or characterizing signaling pathway activation in cell-based models, this antibody provides the consistency and flexibility needed for signal transduction research.